Perilla oil and exercise decrease expressions of tumor necrosis factor-α, plasminogen activator inhibitor-1 and highly sensitive C-reactive protein in patients with hyperlipidemia

Journal of Traditional Chinese Medicine

Volumn 33, Issue 2, 2013, Pages 170-175

  Wei, Minggang ^a   Xiong, Peihua ^a   Zhang, Ling ^a   Fei, Mei ^a   Chen, Aiping ^a   Li, Fengling ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

C reactive protein; Fructus perillae; Hyperlipidemias; Plasminogen activator inhibitor 1; Tumor necrosis factor alpha

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERILLA OIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD EXAMINATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; INJURY; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIVER FUNCTION; SIGNAL TRANSDUCTION; TREATMENT DURATION;

EID: 84879133080     PISSN: 02552922     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0254-6272(13)60120-x     Document Type: Article

References (30)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143-3421.
2. Baseline serum cholesterol and treatment effect in the Scandinavian simvastatin survival study (4S). Lancet 1995; 345(8960): 1274-1275.
3. Influence of pravastatin and plasma lipids on clinical events in the west of Scotland coronary prevention study (WOSCOPS). Circulation 1998, 97(15): 1440-1445.
4. Jukema J W, Bruschke A V, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The regression growth evaluation statin study (REGRESS). Circulation 1995; 91(10): 2528-2540.
5. Maron D J, Fazio S, Linton M F. Current perspectives on statins. Circulation 2000; 101(2): 207-213.
6. Li J J, Li Y S, Chu J M, et al. Changes in plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clin Chim Acta 2005; 366(12): 269-273.
7. Li J J, Fang C H, Qian H Y, Hu W L. Time course of rapid Creactive protein reduction by pravastatin in patients with stable angina. Angiology 2006; 57(1): 1-7.
8. Raison J, Rudnichi A, Safar M E. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens 2002; 16(10): 705-710.
9. Shinohara K, Shoji T, Kimoto E, et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2005; 12(4): 205-210.
10. Wei M G, Xiong P H, Zhang L, Chen A P, Fei M, Li F L. Effect of Perilla Oil Capsule on hyperlipidemia in patients with syndrome of turbid phlegm obstruction. Zhong Cheng Yao 2011; 33(9): 1476-1478.
11. Hu D Y. How to protect and treat the abnormal blood plasma in clinical. Shanghai: TongJi University Press 2006, 10: 66.
12. The Co-committee of the guideline of protecting and treating the high blood plasma for Chinese adult. The guideline of protecting and treating the high blood plasma for Chinese adult. Zhong Hua Xin Xue Guan Bing Za Zhi 2007; 35(5): 390-419.
13. Ross R, Glomset J A. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295(7): 369-377.
14. Ross R. Atherosclerosis: current understanding of mechanisms and future strategies in therapy. Transplant Proc 1993; 25(2): 2041-2043.
15. Ross R. The pathogenesis of atheroselerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
16. Rubins H B, Robins S J, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipo-protein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.
17. Vincent M A, Montagnani M, Quon M J. Molecular and physiologic actions of insulin related to production of nitricoxide in vascular endothelium. Curr Diab Rep 2003; 3: 279-288.
18. Kumada M, Kihara S, Sumitsuji S, et al. Coronary artery disease: association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 123: 85-89.
19. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost 1990; 16(3): 207-216.
20. Vigo C. Effect of C-reactive protein on platelet-activating factorinduced platelet aggregation and membrane stabilization. J Biol Chem 1985; 260(6): 3418.
21. Volanakis J, Narkates A. Binding of human C4 to C-reactive proteinpneumococcal C-polysaccharide complexes during activation of the classical complement pathway. Mol Immunol 1983; 20(11): 1201-1207.
22. Zhang Y, Cliff W, Schoefl G, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999; 145(2): 375-379.
23. Nordestgaard B G, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr Metab Cardiovasc Dis 2009; 19(8): 521-524.
24. Teragawa H, Fukuda Y, Matsuda K. Relation between C reactive protein concentrations and coronary microvascular endothelial function. Heart 2004; 90(7): 750-754.
25. George J, Goldstein E, Abashidze S. Circulating endothelial progenitor cells in patients with unstable angina; association with systemic inflammation. Eur Heart J 2004; 25(12): 1003-1008.
26. Berk B, Weintraub W, Alexander R. Elevation of C-reactive protein in active coronary artery disease. Am J Cardiol 1990; 65(3): 168-172.
27. Cook N R, Buring J E, Ridker P M. The effect of including Creactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006; 145(1): 21.
28. Ridker P M, Buring J E, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98(8): 731-733.
29. Ridker P M, Hennekens C H, Buring J E, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342(12) : 836-843.
30. Xu Z H, Shao Y F, Zhu G H. Influence of perilla oil on rats' blood lipid and blood rheology. Ying Yang Za Zhi 1997; 19(1): 11-15.